A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
A review of Ciclesonide in COVID-19. Still a long way to go
2021
Advances in Respiratory Medicine
Preserved Fulltext
As no definitive therapy or vaccine is yet available for COVID-19, in a desperate attempt repurposed drugs are being explored as an option. A drug repurposing study identified Ciclesonide as a potential candidate. We reviewed the available evidence and clinical trials on the use of Ciclesonide in COVID-19. At present the evidence is limited to a report of three cases. However, five clinical trials are underway, and their results will help in elucidating the role of Ciclesonide in COVID-19.
doi:10.5603/arm.a2020.0173
pmid:33471354
fatcat:qtbo7hzbdvhepcl3yowvwz4rwu